Akeso’s IL-4Rα/ST2 Antibody Cleared for Seven Phase II Trials
Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a...
Tag : Akeso
Akeso’s Cadonilimab Approved for 1st-Line Cervical Cancer Treatment
Akeso, Inc. is pleased to announce that the National Medical Products Administration (NMPA) has approved the company’s first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line...